Table 1.
Clinical and demographic features of anti-MOG-IgG-positive patients (N=42).
| Number | M/F | Age of onset (median years) | Disease duration (median months) | Duration of follow-up (median months) | |
|---|---|---|---|---|---|
| Total | 42 | 24/18 | 21.0 (6–53) | 57.6 (12.0–336) | 36.0 (12.0–84) |
| Monophasic disease | |||||
| Total | 18 | 10/8 | 22.0 (10–53) | 36.0 (12.0–84) | 36.0 (12.0–84) |
| ATM | 14 | 10/4 | 27.5 (16–53) | 36.0 (12.0–108) | 36.0 (12.0–108) |
| ADEM | 2 | 0/2 | 17.5 (15–20) | 69.6 (67.2–72) | 69.6 (67.2–72) |
| ON | 2 | 0/2 | 12.0 (10–14) | 30.0 (24.0–36) | 30.0 (24.0–36) |
| Recurrent disease | |||||
| Total | 24 | 14/10 | 19.0 (5–42) | 72.0 (12.0–336) | 24.0 (12.0–84) |
| NMOSD | 8 | 5/3 | 22.5 (7–49) | 33.6 (12.0–120) | 18.0 (12.0–72) |
| RTM | 3 | 3/0 | 6.0 (7–12) | 144.0 (72.0–336) | 24.0 (24.0–36) |
| RON | 13 | 6/7 | 21.0 (5–42) | 72.0 (20.4–240) | 48.0 (19.2–84) |
ATM: acute transverse myelitis; ADEM: acute disseminated encephalomyelitis; ON: optic neuritis: NMOSD: neuromyelitis optica spectrum disorder; RTM: recurrent transverse myelitis; RON: recurrent optic neuritis.